Quantcast

Latest Acthar Stories

2014-07-11 23:01:56

A recent regulatory filing exposes that the number of adverse events in 2013 reported by patients taking Acthar was almost 14% of prescriptions. Zoll, Kranz & Borgess is investigating this potentially dangerous drug. Toledo, Ohio (PRWEB) July 11, 2014 As reported by the New York Times (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of severe adverse events such as renal failure, increases in blood sugar, abdominal issues and even death from the...

2014-05-14 08:32:08

- Expands pipeline and broadens platform with next-generation melanocortin peptides - ANAHEIM, Calif., May 14, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen(®),...

2014-05-05 08:30:03

- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - ANAHEIM, Calif., May 5, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated...

2014-04-28 16:31:16

- Net Sales $227 Million; Increase 68% Year-over-Year - ANAHEIM, Calif., April 28, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2014. Three Months Ended 03/31/14 Three Months Ended 03/31/13 Percentage Change ------------------------------ ------------------------------ ----------------- Net Sales $227.1 Million $135.1...

2014-04-21 08:26:07

- Clinical results appear to correlate with reduction in anti-PLA2R antibodies ANAHEIM, Calif., April 21, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from an investigator-initiated clinical study involving two major academic research centers examining the dosing and effectiveness of H.P. Acthar® Gel (repository corticotropin) in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN) have been published in the...

2014-04-07 08:29:44

--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- DUBLIN and ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction...

2014-02-25 16:29:30

- Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year - ANAHEIM, Calif., Feb. 25, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2013. Three Months Ended 12/31/13 Three Months Ended 12/31/12 Percentage Change ------------------------------ ------------------------------ ----------------- Net Sales $242.9...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related